**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 63338

**Manuscript Type:** MINIREVIEWS

**Large-duct pattern invasive adenocarcinoma of the pancreas–a variant mimicking pancreatic cystic neoplasms: A minireview**

Sato H *et al*. Large-duct pattern invasive pancreatic cancer

Hiroki Sato, Andrew Scott Liss, Yusuke Mizukami

**Hiroki Sato, Yusuke Mizukami,** Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 0788510, Hokkaido, Japan

**Hiroki Sato, Andrew Scott Liss,** Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, United States

**Yusuke Mizukami,** Institute of Biomedical Research, Sapporo Higashi Tokushukai Hospital, Sapporo 0650033, Hokkaido, Japan

**Author contributions:** Sato H wrote and edited the manuscript and collected clinical and pathological data; Mizukami Y reviewed the discussion on pathological findings and genetic alterations in the manuscript; Liss AS revised the manuscript and provided recommendations for the manuscript; all authors have read and approved the final manuscript.

**Supported by** Japan Society for the Promotion of Science (JSPS) KAKENHI, No. 19K17480 (to Sato H), and No. 20H03655 (Mizukami Y).

**Corresponding author: Hiroki Sato, MD, Academic Fellow, Doctor, Research Fellow,** Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 1-1, Midorigaoka Higashi 2-1, Asahikawa 0788510, Hokkaido, Japan. hirokisato@asahikawa-med.ac.jp

**Received:** January 28, 2021

**Revised:** March 9, 2021

**Accepted:** May 17, 2021

**Published online:**

**Abstract**

Pancreatic cancer currently has no subtypes that inform clinical decisions; hence, there exists an opportunity to rearrange the morphological and molecular taxonomy that guides a better understanding of tumor characteristics. Nonetheless, accumulating studies to date have revealed the large-duct type variant, a unique subtype of pancreatic ductal adenocarcinoma (PDA) with cystic features. This subtype often radiographically mimics intraductal papillary mucinous neoplasms (IPMNs) and involves multiple small cysts occasionally associated with solid masses. The “bunch-of-grapes” sign, an imaging characteristic of IPMNs, is absent in large-duct PDA. Large-duct PDA defines the mucin profile, and genetic alterations are useful in distinguishing large-duct PDA from IPMNs. Histologically, neoplastic ducts measure over 0.5 mm, forming large ductal elements. Similar to classic PDAs, this subtype is frequently accompanied by perineural invasion and abundant desmoplastic reactions, and *KRAS* mutations in codon 12 are nearly ubiquitous. Despite such morphological similarities with IPMNs, the prognosis of large-duct PDA is equivalent to that of classic PDA. Differential diagnosis is therefore essential.

**Key Words:** Large-duct pattern invasive carcinoma of the pancreas; Pancreatic ductal adenocarcinoma; Pancreatic cystic disease; Clinicopathological features of pancreatic cancer; Pancreatic cancer subtype

Sato H, Liss AS, Mizukami Y. Large-duct pattern invasive adenocarcinoma of the pancreas–a variant mimicking pancreatic cystic neoplasms: A minireview. *World J Gastroenterol* 2021; In press

**Core Tip:** This review integrates the current knowledge about large-duct pattern invasive adenocarcinoma of the pancreas [large-duct pancreatic ductal adenocarcinoma (PDA)]. This subtype is a rare exocrine pancreatic neoplasm and often mimics intraductal papillary mucinous neoplasms (IPMNs). However, its prognosis is notably different from that of IPMNs, and distinguishing this subtype from IPMNs preoperatively is crucial. We summarized the morphological features and genetic landscape of large-duct PDA, with a primary focus on its differences from other types of pancreatic cystic neoplasms. The information aid in making appropriate decisions when tackling atypical pancreatic cystic neoplasms.

**INTRODUCTION**

Pancreatic cancer is one of the most devastating and fatal diseases in humans, with pancreatic ductal adenocarcinoma (PDA) being the most common exocrine pancreatic neoplasm[1]. With the increase in the number of patients, PDA is expected to become the second leading cause of cancer-related mortality worldwide[2,3]. Advances in multidisciplinary treatment have improved patient survival and have enhanced the effectiveness of modalities for the early detection and identification of cancer subtypes. Despite all efforts to prolong survival, PDA represents one of the worst tumors, with a 5-year overall survival rate of only 2%-9%[4]. Molecular subtyping of this tumor based on genetic signatures has been developed over the past 10 years; nevertheless, the correlation of such information with clinical phenotypes has been somewhat evasive.

Macroscopically, PDA is characterized by yellowish-white masses, usually without hemorrhagic necrosis[5,6]. On histological examination, typical PDA exhibits duct-like glandular structures infiltrating the pancreatic parenchyma, eliciting a strong desmoplastic stromal response[7,8]. The neoplastic cells are columnar to cuboidal and produce various mucins, depending on differentiation and histotypes. Several genetic alterations such as *KRAS* (chromosome 12p), *SMAD4* (chromosome 18q), *CDKN2A* (chromosome 9p), and *TP53* (chromosome 17p) are responsible for causing PDA[9-11] that progresses from low-grade pancreatic intraepithelial neoplasia (PanIN) to higher-grade PanIN and invasive PDA[12-16].

PDA accounts for up to 90% of pancreatic neoplasms and is typically visualized as a solid mass accompanied by abundant desmoplasia[17]. However, tumors with cystic components occasionally compose a small subset in approximately 4%-5% of patients. Colloid carcinoma, a subtype of PDA that is often conjugated to intraductal papillary mucinous neoplasms (IPMNs), is characterized by extracellular mucin pools. Morphologically, colloid carcinoma tends to exhibit a large, well-demarcated cystic lesion[18]. This subtype of PDA originates, at least in part, from IPMNs, which are well-known pancreatic cystic neoplasms[19-21]. IPMNs can be categorized into two morphologically distinct types — namely, the branched type and main duct type[22,23]. Furthermore, multiple subsets, including gastric, intestinal, and pancreatobiliary types, are histologically defined[24]. These types have unique paths during development and progression to invasive tumors[25], and specific genetic alterations observed in IPMNs may be responsible for tumor phenotypes and ultimately influence the patients’ outcome[26,27]. In most cases, other pancreatic lesions with cystic features, such as solid cystic neoplasm (SCN)[28,29], mucinous cystic neoplasm (MCN)[30], and solid pseudopapillary neoplasm (SPN)[28], can be easily distinguished from classic PDA[31]; however, atypical imaging findings of patients occasionally impair proper diagnosis. Knowledge and use of relevant genetic alterations unique to these cystic neoplasms may aid patients and physicians in making appropriate decisions.

Recent studies have revealed a histological subtype of PDA with cystic features mimicking pancreatic cystic diseases[32]. This PDA variant is referred to as large-duct pattern invasive adenocarcinoma of the pancreas (large-duct type) and is characterized by invasive PDA forming large, sometimes dilatated glands. Nevertheless, this entity is considered rare and often leads to the misdiagnosis of several pancreatic cystic neoplasms, including IPMNs. This review compares the clinical characteristics, gross morphology and histopathology, and genetic alterations of large-duct PDA and other pancreatic cystic neoplasms.

**CLINICAL MANIFESTATIONS**

***Epidemiology***

Large-duct PDA has been estimated to occur in < 7% of all PDA cases. It has been reported in only 63 patients in the past literature[33-35]. Large-duct PDA has been initially diagnosed as IPMN in most cases[34]; hence, the incidence of large-duct PDA has not been clearly recognized. Thus, regarding incidence, large-duct PDA of the pancreas is considered rare[36]. The median age of these patients with large-duct PDA was 63.0 years, and the sex ratio was female-dominant, with a female-to-male ratio of 1.73 (Table 1). The female-to-male ratio was higher in patients with large-duct PDA than in those without large-duct PDA[18]. A previous study reported no specific and unique risk factors.

***Tumor location and symptoms***

Generally, 60% of classic PDAs develop in the pancreatic head[37], and the majority of the patients exhibit symptoms associated with obstructive jaundice. A summary of previously reported cases with large-duct PDA indicated similar tumor locations (Table 1). Kelly *et al*[34] reported that 2 out of 9 patients with large-duct PDA had jaundice. Other patients had acute pancreatitis (*n* = 1) and abdominal pain (*n* = 5).

**IMAGING FINDINGS**

***Computed tomography imaging***

Dynamic contrast-enhanced computed tomography imaging is an essential modality for assessing cystic lesions in the pancreas. Typical PDA presents as a solid and hypovascular tumor, and the most common radiographic finding of PDA is dilatation or stricture of the main pancreatic duct. In contrast, large-duct PDA usually presents as a cluster of small cystic lesions. The diameter of cysts generally measures 5-7 mm, although they sometimes exceed 10 mm[38]. However, large-duct PDA does not have a “bunch-of-grapes” appearance[39], commonly detected in IPMNs. Given the multiple small cysts visualized on cross-sectional images, distinguishing them from SCN is more complicated, particularly in cases with macrocystic-type cysts[40]. SCN typically has a spongy or honeycomb-like appearance; one previous report described a large-duct PDA case showing a honeycomb-like morphology[36]. Large-duct PDA lacks either a star-shaped scar or calcification at the center of the cyst, commonly observed in SCN[38,41,42]. Considering the female-dominated epidemiology, MCN is also a significant differential diagnosis. MCN has an orange-like appearance and sometimes forms cystic lesions measuring over 10 cm; these features are not typical in large-duct PDA[42,43].

Another critical finding suggestive of the large-duct pattern is the slightly diminished enhancement of the parenchyma surrounding cystic components (Figure 1). Similar to typical PDA, such enhancement gradually increases with time after contrast media injection. Furthermore, walled-off necrosis (WON) should be excluded. WON often contains debris and hemorrhage in cysts, resulting in a mixed density change in the fluid[44,45]. These findings are not usually observed in large-duct PDA. Retention cysts often occur along with PDA and are also important in distinguishing it from large-duct PDA. Retention cysts are typically unilocular and tend to be larger than the cysts observed in large-duct PDA[46,47] (Table 2).

***Magnetic resonance imaging***

Magnetic resonance cholangiopancreatography is another essential modality for diagnosing pancreatic cystic diseases, except in claustrophobic individuals and those with implanted magnetic resonance imaging-unsafe foreign bodies. Crucial findings for large-duct PDA include small cysts in the pancreas[48], with each cyst usually having a diameter of 0.5-0.7 cm[49]. It should be noted that pancreatic duct dilatation in the pancreatic tail and pancreatic duct stricture is more intense than that observed in other cystic neoplasms. Stricture of the main pancreatic duct and bile duct closely associated with a cluster of small cysts is another finding that we may consider when diagnosing large-duct PDA (Figure 2). In making a differential diagnosis of IPMNs, communication with the main pancreatic duct is crucial. Both typical main duct-type and branched duct-type IPMNs communicate with the main pancreatic duct and often show dilatation of the main pancreatic duct[41,50,51].

Moreover, diffusion-weighted imaging and apparent diffusion coefficient map on magnetic resonance cholangiopancreatography is helpful in diagnosing PDA. Considering the high intensity of cystic lesions on T2-weighted images[52,53], diffusion-weighted imaging may not help distinguish large-duct PDA from other pancreatic cystic diseases (Figure 2).

***Endoscopic findings***

Endoscopic ultrasonography (EUS) has the highest sensitivity for detecting PDA lesions[54], specifically small-sized tumors. Irrespective of the size of PDA, non-neoplastic cystic changes associated with PDA include retention cysts caused by ductal obstruction, and pseudocysts attributable to tumor-associated pancreatitis may be considered to distinguish it from large-duct type tumors[55,56]. A “mucinous clot,” which is a hyperechoic lesion inside cysts, is sometimes visualized using EUS in patients with IPMNs, but not in those with large-duct PDAs[57,58]. Furthermore, large-duct PDAs typically lack mural nodules and papillary growth, signatures of high-risk stigmata, and worrisome features in the Fukuoka criteria[41,59]. Youn *et al*[38] described a case of large-duct PDA with a solid mass inside a dilatated glandular cyst[38]. Such atypical findings make a differential diagnosis between large-duct PDAs and IPMNs with high-risk stigmata confusing among endoscopists; nonetheless, surgical resection should be performed for either disease. Considering the multifocality of IPMNs, performing EUS for multifocal lesions, which are not observed in large-duct PDA, is crucial (Table 2)[41,51]. The morphology of “cyst by cyst” appearance can be observed in typical IPMNs using EUS[41].

No report has specifically described EUS-guided fine-needle aspiration (EUS-FNA) in patients with large-duct PDA. In the case of pancreatic tumors with cystic components, concerns related to tumor cell dissemination from the cystic fluid (needle tract seeding)[60] may need to be pointed out (Figure 3). Thus, drawing a distinction between large-duct PDA and IPMN-associated cancer using EUS-FNA can become highly challenging, which will be explained well in the “Pathology” section. The requirements for preoperative histological diagnosis of PDA have increased in the neoadjuvant chemotherapy era; therefore, an ingenious solution for the safe and accurate diagnosis of large-duct PDA using EUS-FNA needs to be considered. No report regarding endoscopic retrograde cholangiopancreatography has described specific findings for large-duct PDA. For tumors developing in the pancreatic head, transpapillary biopsy for histological diagnosis can be useful if massive bile duct invasion is evident.

**PATHOLOGY**

***Macroscopic features***

Bagci *et al*[33] described 28 cases of large-duct PDA. Macroscopically, 10 patients had a cyst measuring < 10 mm, whereas 1 patient had a large cyst over 70 mm[33]. Pathologically, each small cyst is a dilatated glandular carcinoma. Similarly, Kosmahl *et al*[35]*.* described 24 cases of large-duct PDA and reported a diameter ranging from 4 to 18 mm for each cyst; the gross tumor size was not different from ordinary PDA[35]. The entire cystic lesion size is crucial, and the cystic component of large-duct PDA is less than 100 mm generally. In comparison, the size of cysts in MCN, SCN, or pancreatic neuroendocrine neoplasms (PanNENs) sometimes exceeds 100 mm (Table 2)[61,62].

***Microscopic features***

Microscopically, large-duct PDA shows dilatated glands that range in size from 5 to 10 mm. The term “large duct” is defined as dilatation greater than 0.5 mm among ≥ 50% of glands in PDA[33]. Hematoxylin–eosin staining has revealed some essential pathological findings for large-duct PDA. The nuclei of the epithelial carcinoma (dilatated glands) are irregular, wrinkled, and basally located. The cytoplasm exhibits a foamy or microvesicular pattern, and the glands are jagged and irregular[34]. While a papillary growth pattern is typically absent, discrimination of large-duct PDA from other cystic neoplasms, especially gastric-type IPMNs, is crucial[63,64]. In contrast to mucinous carcinoma, large-duct PDA lacks signet ring cells or mucinous lakes[65,66].

Perineural invasion is another important finding for diagnosing large-duct PDA to discriminate from other cystic neoplasms. Bagci *et al*[33] reported that perineural invasion occurred in 88% of large-duct PDAs[33] but was less commonly observed in IPMNs, even though the tumor had invasive compartments. In large-duct PDA, the stroma has a rich desmoplastic appearance[33,34]. These features are commonly observed in PDA compared to IPMNs; however, they are more remarkable in large-duct PDA. Additionally, hypercellular stroma or ovarian-like stroma is present in some cases.As for the differential diagnosis of colloid carcinoma or PanNENs, the cysts in these lesions are relatively well-demarcated relative to those in large-duct PDA. PanNENs sometimes have a thick fibrous capsule with hemorrhage[61]. WON usually shows necrotic debris in cysts. Macroscopically, this finding is usually not observed in large-duct PDA and can be a point to distinguish one from other cystic lesions[67].

***Immunohistochemistry***

Immunohistochemistry (IHC) may be a crucial diagnostic tool that can be utilized to discriminate large-duct PDA from other pancreatic cystic neoplasms[36]. Among the immunostaining widely used in the diagnosis of tumors, mucin (MUC) staining is particularly important and may play a key role in diagnosing large-duct PDA. Gastric-type IPMN exhibits relatively low papillary growth[64] and is typically low grade. However, in tumors with high-grade gastric IPMN, distinction from the large-duct type PDA is sometimes uncertain pathologically. IPMNs present unique MUC staining patterns, depending on the epithelial subtypes[63]. Gastric-type IPMNs show MUC5AC-positive staining patterns and are negative for MUC1, MUC2, and MUC6. Kelly *et al*[34] and Kosmahl *et al*[35] reported MUC staining for large-duct PDAs (Table 3)[34,35]; the positivity rates of MUC1, MUC2, MUC5AC, and MUC6 immunostaining were 79.4%, 8.8%, 78.8%, and 60.6%, respectively. Thus, MUC1 and MUC6 IHC may help make a differential diagnosis from IPMNs[68].

Furthermore, P53 IHC is beneficial in diagnosing lesions with malignant potential. Bagci *et al*[33] showed that 73% of all large-duct PDAs positively stained for p53. Another point of IHC for large-duct PDA is whether the dilatated glands are dilatated glandular carcinomas or dilatated glands resulting from the occlusion of upper-stream pancreatic ducts. To presume the origin of anatomical localization of the dilated pancreatic ducts, Elastica–Masson staining may be suitable (Figure 4). In addition to the main pancreatic duct, elastin fibers in these normal pancreatic ducts can be stained with Elastica–Masson. Typically, the dilatated glands in large-duct PDA are negative for the immunostaining, suggesting they were derived from tumor glands rather than the secondary dilation of the normal main pancreatic duct and associated large branch duct[69].

**GENETIC ALTERATIONS**

*KRAS* is mutated in the great majority of PDA, and approximately 90%-95% of PDA patients have major hot spot mutations in codons 12, 13, and 61[9]. This genetic event has been identified at the earliest stages of PanIN, and studies in genetically engineered mice models (GEMMs) indicate that PanINs arise from pancreatic acinar cells that incur Kras mutations (Ptf1a-induced Kras activation). In the KrasG12D-expressing mice, PanIN formation coincides with acinar-to-ductal metaplasia (ADM), characterized by the replacement of acinar cells with cells expressing ductal markers, such as CK19 and the ductal fate determinant Sox9[70]. Further, propensity of ductal and centroacinar cells to give rise to PanINs is demonstrated by GEMM with Sox9CreER-mediated Kras activation, although considerably less frequent relative to Ptf1aCreER-induced Kras activation[71].

Although observations in these mice models have not been validated in humans, multiple PanIN-like lesions with various grades of atypia can often be observed in the “normal area” of the resected specimens of pancreatic cancer. These lesions are usually solitary and localized in the normal acinar compartment without pancreatitis. However, PanINs associated with a cluster of ADM can also be seen[9]. Nevertheless, it remains to be determined if the PDA, including large-duct type, originated from either differentiated duct or duct-like cells associated with ADM. Such hypothesis may be clarified based on the particular mutation profiles and molecular signature related to cellular origin.

Moreover, genetic analysis is valuable in establishing a differential diagnosis between large-duct PDA and IPMNs. Bagci *et al*[33] conducted a mutation analysis of *KRAS* codon 12, which is the most frequent mutation point in PDA, using specimens from 28 large-duct PDA patients compared to ordinary ductal adenocarcinoma of the pancreas[33]. The results indicated 82% of large-duct PDAs harbored *KRAS* codon 12 mutations, a bit less frequency observed in classic PDAs (generally over 90%)[33,72]. Since the authors utilized slot-blot Southern analysis of polymerase chain reaction-amplified samples, *KRAS* mutation in codon 12 might be missed in case of the tumor with low tumor cellularity, and latest methods may also identify other hotspots at codons 13 and 61. Additionally, IPMN can be initiated by *KRAS* mutation[9], although less frequently than PanIN[73,74] . *KRAS* mutations are observed in 53%-87% of gastric-type IPMNs and approximately 40% in intestinal-type IPMNs. In contrast to PDAs including large-duct type, IPMNs frequently harbor multiple different types of *KRAS* mutations, suggesting poly-clonal diseases[25]. Therefore, specifying the variation in *KRAS* mutation types may be valuable in determining a subset of patients with large-duct PDA.

*TP53* gene is also frequently mutated around 75% of pancreatic carcinoma patients[75], and Bagci *et al*[33] reported that abnormal immunostaining of p53 was observed in 73% of large-duct type PDA, a higher frequency relative to classic PDA (60%). Moreover, *TP53* mutation can be seen in 10%-40% of high-grade IPMNs and 40%-60% of IPMN-associated invasive carcinomas[73,76]. Given the strong gain-of-function of particular missense mutations in *TP53* relative to the truncating mutations[77,78], further studies will be required if such *TP53* mutation typesare associated with the tumor phenotypes. *SMAD4* is also inactivated in 55% of PDA cases; of these, 35% are inactivated by homozygous deletion, whereas 20% show loss of one allele[10]. Inactivation of *SMAD4* enhances the rapid progression of *Kras*G12D-initiated mice pancreatic neoplasms, showing IPMN-like phenotypes[79], and a significant fraction of IPMN-associated human pancreatic cancer harbors *SMAD4* mutation and the abnormal immunostaining[25]. Whether *SMAD4* inactivation can influence the progression or promotion of large-duct PDA remains unclear.

*GNAS* mutations are unique to IPMNs[80,81] and are more frequently identified in intestinal-type IPMNs than in gastric- and pancreatobiliary-type IPMNs[9]. The mutation can progress to IPMN-associated PDA, and recent studies demonstrated that about 8%-11% of pancreatic cancers[9], including cases considered not related explicitly to IPMN, harbor *GNAS* mutations or amplifications. Since *GNAS* mutation can lead to entirely distinct transcriptional and metabolic reprogramming to *KRAS*-driven circuitry[82], identification of *GNAS* mutations may discriminate large-duct PDA from IPMN-related pancreatic cancer.

*RNF43* encodes an E3 ubiquitin ligase. *RNF43* mutations are observed in IPMNs and MCNs and are detected in approximately 50% of all IPMNs[83]. Nonetheless, a recent meta-analysis has suggested that *RNF43* mutations are not associated with clinicopathologic parameters in patients with IPMN[83,84]. Approximately 50% of MCNs present *RNF43* mutations, including loss of heterozygosity[85]. Other cystic neoplasms in the pancreas exhibit specific genetic mutations. Genetic alterations such as *VHL* mutations and loss of heterozygosity in SCN, *CTNNB1*, and *PIK3CA* mutations in SPN and PanNEN-associated mutations (*MEN1*, *PTEN*, *DAXX*, and *ATRX*) have been specifically identified in SCNs and PanNENs, particularly in cases with cystic components resembling retention cysts[85,86] (Table 2).

Further genetic analysis should be performed in the large-duct PDA, considering whether the cellular origin of the large-duct PDA was the branch or main pancreatic duct and pathways of carcinogenesis[87,88]. Whole-genome sequencing may be helpful in determining the genes responsible for forming large-duct glands[87,89].

**TREATMENT AND PROGNOSIS**

Large-duct PDA has been recognized as an uncommon subtype of PDA. Hence, in previous reports, large-duct PDA was mainly diagnosed from surgically resected specimens[33,34]. Preoperative diagnosis was variable, including IPMN, MCN, and “PDA with solid and cystic mass.” Furthermore, the patients in these reports were diagnosed at an advanced stage, and the period of survival after resections was about 7-16 mo. These reports were published in the era when adjuvant or neoadjuvant chemotherapy for PDA was not established. The outcome is worse than that of surgically resected IPMNs, reported as 37.0 mo[90], and chemotherapy is not generally considered if the invasive component in IPMN-associated cancer is not evident. Therefore, distinguishing large-duct PDA from other cystic neoplasms, including IPMNs, is essential. Accurate histological and genomic information related to the tumor will help decide between appropriate therapeutic options before surgery[91-93]. Currently, how standard chemotherapy against PDAs, including both adjuvant and neoadjuvant chemotherapy, can effectively eradicate large-duct PDAs remains unclear.

**CONCLUSION**

Large-duct PDA is a subtype of PDA that mimics IPMNs or other pancreatic cystic neoplasms. Given the rarity of this disease, the diagnostic approach is sometimes challenging. Considering the estimated prognosis of the patients, it is crucial to distinguish large-duct PDAs from IPMNs using macroscopic and pathological findings. When an atypical cystic lesion is identified in the pancreas, both symptomatic and asymptomatic, the differential diagnosis should include large-duct PDA. Given their advantages, genetic analysis of PDAs and IPMNs, exploration of *KRAS* mutations, and mutation profiling of other cancer-related genes may help establish an accurate diagnosis.

**ACKNOWLEDGEMENTS**

We thank Hiroyuki Maguchi at Teine Keijinkai Hospital for providing support in the pathological and clinical diagnoses, as well as the members of the Department of Medicine at Asahikawa Medical University for carefully reading and examining the manuscript.

**REFERENCES**

1 **Fitzgerald TL**, Hickner ZJ, Schmitz M, Kort EJ. Changing incidence of pancreatic neoplasms: a 16-year review of statewide tumor registry. *Pancreas* 2008; **37**: 134-138 [PMID: 18665072 DOI: 10.1097/MPA.0b013e318163a329]

2 **Rahib L**, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res* 2014; **74**: 2913-2921 [PMID: 24840647 DOI: 10.1158/0008-5472.CAN-14-0155]

3 **Goess R**, Friess H. A look at the progress of treating pancreatic cancer over the past 20 years. *Expert Rev Anticancer Ther* 2018; **18**: 295-304 [PMID: 29334794 DOI: 10.1080/14737140.2018.1428093]

4 **McGuigan A**, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. *World J Gastroenterol* 2018; **24**: 4846-4861 [PMID: 30487695 DOI: 10.3748/wjg.v24.i43.4846]

5 **Schlitter AM**, Jesinghaus M, Jäger C, Konukiewitz B, Muckenhuber A, Demir IE, Bahra M, Denkert C, Friess H, Kloeppel G, Ceyhan GO, Weichert W. pT but not pN stage of the 8th TNM classification significantly improves prognostication in pancreatic ductal adenocarcinoma. *Eur J Cancer* 2017; **84**: 121-129 [PMID: 28802189 DOI: 10.1016/j.ejca.2017.06.034]

6 **He J**, Ahuja N, Makary MA, Cameron JL, Eckhauser FE, Choti MA, Hruban RH, Pawlik TM, Wolfgang CL. 2564 resected periampullary adenocarcinomas at a single institution: trends over three decades. *HPB (Oxford)* 2014; **16**: 83-90 [PMID: 23472829 DOI: 10.1111/hpb.12078]

7 **Schlitter AM**, Segler A, Steiger K, Michalski CW, Jäger C, Konukiewitz B, Pfarr N, Endris V, Bettstetter M, Kong B, Regel I, Kleeff J, Klöppel G, Esposito I. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes. *Sci Rep* 2017; **7**: 41064 [PMID: 28145465 DOI: 10.1038/srep41064]

8 **Hruban RH**, Maitra A, Kern SE, Goggins M. Precursors to pancreatic cancer. *Gastroenterol Clin North Am* 2007; **36**: 831-849, vi [PMID: 17996793 DOI: 10.1016/j.gtc.2007.08.012]

9 **Patra KC**, Bardeesy N, Mizukami Y. Diversity of Precursor Lesions For Pancreatic Cancer: The Genetics and Biology of Intraductal Papillary Mucinous Neoplasm. *Clin Transl Gastroenterol* 2017; **8**: e86 [PMID: 28383565 DOI: 10.1038/ctg.2017.3]

10 **Hahn SA**, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. *Science* 1996; **271**: 350-353 [PMID: 8553070 DOI: 10.1126/science.271.5247.350]

11 **Caldas C**, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. *Nat Genet* 1994; **8**: 27-32 [PMID: 7726912 DOI: 10.1038/ng0994-27]

12 **Real FX**. A "catastrophic hypothesis" for pancreas cancer progression. *Gastroenterology* 2003; **124**: 1958-1964 [PMID: 12806629 DOI: 10.1016/s0016-5085(03)00389-5]

13 **Hata T**, Suenaga M, Marchionni L, Macgregor-Das A, Yu J, Shindo K, Tamura K, Hruban RH, Goggins M. Genome-Wide Somatic Copy Number Alterations and Mutations in High-Grade Pancreatic Intraepithelial Neoplasia. *Am J Pathol* 2018; **188**: 1723-1733 [PMID: 29684357 DOI: 10.1016/j.ajpath.2018.03.012]

14 **Wilentz RE**, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, Yeo CJ, Kern SE, Hruban RH. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. *Cancer Res* 2000; **60**: 2002-2006 [PMID: 10766191]

15 **Cáceres M**, Quesada R, Iglesias M, Real FX, Villamonte M, de Villarreal JM, Pérez M, Andaluz A, Moll X, Berjano E, Dorcaratto D, Sánchez-Velázquez P, Grande L, Burdío F. Pancreatic duct ligation reduces premalignant pancreatic lesions in a Kras model of pancreatic adenocarcinoma in mice. *Sci Rep* 2020; **10**: 18344 [PMID: 33110094 DOI: 10.1038/s41598-020-74947-4]

16 **Kaneda A**, Matsusaka K, Aburatani H, Fukayama M. Epstein-Barr virus infection as an epigenetic driver of tumorigenesis. *Cancer Res* 2012; **72**: 3445-3450 [PMID: 22761333 DOI: 10.1158/0008-5472.CAN-11-3919]

17 **Di Maggio F**, El-Shakankery KH. Desmoplasia and Biophysics in Pancreatic Ductal Adenocarcinoma: Can We Learn From Breast Cancer? *Pancreas* 2020; **49**: 313-325 [PMID: 32168249 DOI: 10.1097/MPA.0000000000001504]

18 **Seidel G**, Zahurak M, Iacobuzio-Donahue C, Sohn TA, Adsay NV, Yeo CJ, Lillemoe KD, Cameron JL, Hruban RH, Wilentz RE. Almost all infiltrating colloid carcinomas of the pancreas and periampullary region arise from in situ papillary neoplasms: a study of 39 cases. *Am J Surg Pathol* 2002; **26**: 56-63 [PMID: 11756769 DOI: 10.1097/00000478-200201000-00006]

19 **Hecht EM**, Khatri G, Morgan D, Kang S, Bhosale PR, Francis IR, Gandhi NS, Hough DM, Huang C, Luk L, Megibow A, Ream JM, Sahani D, Yaghmai V, Zaheer A, Kaza R. Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: recommendations for Standardized Imaging and Reporting from the Society of Abdominal Radiology IPMN disease focused panel. *Abdom Radiol (NY)* 2021; **46**: 1586-1606 [PMID: 33185741 DOI: 10.1007/s00261-020-02853-4]

20 **Nasca V**, Chiaravalli M, Piro G, Esposito A, Salvatore L, Tortora G, Corbo V, Carbone C. Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk Stratification. *Int J Mol Sci* 2020; **21** [PMID: 32887490 DOI: 10.3390/ijms21176386]

21 **Zaccari P**, Cardinale V, Severi C, Pedica F, Carpino G, Gaudio E, Doglioni C, Petrone MC, Alvaro D, Arcidiacono PG, Capurso G. Common features between neoplastic and preneoplastic lesions of the biliary tract and the pancreas. *World J Gastroenterol* 2019; **25**: 4343-4359 [PMID: 31496617 DOI: 10.3748/wjg.v25.i31.4343]

22 **Lu C**, Xu CF, Wan XY, Zhu HT, Yu CH, Li YM. Screening for pancreatic cancer in familial high-risk individuals: A systematic review. *World J Gastroenterol* 2015; **21**: 8678-8686 [PMID: 26229410 DOI: 10.3748/wjg.v21.i28.8678]

23 **Chang YR**, Park JK, Jang JY, Kwon W, Yoon JH, Kim SW. Incidental pancreatic cystic neoplasms in an asymptomatic healthy population of 21,745 individuals: Large-scale, single-center cohort study. *Medicine (Baltimore)* 2016; **95**: e5535 [PMID: 28002329 DOI: 10.1097/MD.0000000000005535]

24 **Adsay V**, Mino-Kenudson M, Furukawa T, Basturk O, Zamboni G, Marchegiani G, Bassi C, Salvia R, Malleo G, Paiella S, Wolfgang CL, Matthaei H, Offerhaus GJ, Adham M, Bruno MJ, Reid MD, Krasinskas A, Klöppel G, Ohike N, Tajiri T, Jang KT, Roa JC, Allen P, Fernández-del Castillo C, Jang JY, Klimstra DS, Hruban RH; Members of Verona Consensus Meeting, 2013. Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting. *Ann Surg* 2016; **263**: 162-177 [PMID: 25775066 DOI: 10.1097/SLA.0000000000001173]

25 **Omori Y**, Ono Y, Tanino M, Karasaki H, Yamaguchi H, Furukawa T, Enomoto K, Ueda J, Sumi A, Katayama J, Muraki M, Taniue K, Takahashi K, Ambo Y, Shinohara T, Nishihara H, Sasajima J, Maguchi H, Mizukami Y, Okumura T, Tanaka S. Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features. *Gastroenterology* 2019; **156**: 647-661.e2 [PMID: 30342036 DOI: 10.1053/j.gastro.2018.10.029]

26 **Schönleben F**, Qiu W, Bruckman KC, Ciau NT, Li X, Lauerman MH, Frucht H, Chabot JA, Allendorf JD, Remotti HE, Su GH. BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. *Cancer Lett* 2007; **249**: 242-248 [PMID: 17097223 DOI: 10.1016/j.canlet.2006.09.007]

27 **Tan MC**, Basturk O, Brannon AR, Bhanot U, Scott SN, Bouvier N, LaFemina J, Jarnagin WR, Berger MF, Klimstra D, Allen PJ. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma. *J Am Coll Surg* 2015; **220**: 845-854.e1 [PMID: 25840541 DOI: 10.1016/j.jamcollsurg.2014.11.029]

28 **Chagas VL**, Rosman FC, Carvalho MDGDC. Solid pseudopapillary neoplasia of the pancreas: a review. *Rev Assoc Med Bras (1992)* 2020; **66**: 87-94 [PMID: 32130387 DOI: 10.1590/1806-9282.66.1.87]

29 **Gandhi D**, Sharma P, Parashar K, Kochar PS, Ahuja K, Sawhney H, Sharma S. Solid pseudopapillary Tumor of the Pancreas: Radiological and surgical review. *Clin Imaging* 2020; **67**: 101-107 [PMID: 32559679 DOI: 10.1016/j.clinimag.2020.06.008]

30 **Nilsson LN**, Keane MG, Shamali A, Millastre Bocos J, Marijinissen van Zanten M, Antila A, Verdejo Gil C, Del Chiaro M, Laukkarinen J. Nature and management of pancreatic mucinous cystic neoplasm (MCN): A systematic review of the literature. *Pancreatology* 2016; **16**: 1028-1036 [PMID: 27681503 DOI: 10.1016/j.pan.2016.09.011]

31 **Hasan A**, Visrodia K, Farrell JJ, Gonda TA. Overview and comparison of guidelines for management of pancreatic cystic neoplasms. *World J Gastroenterol* 2019; **25**: 4405-4413 [PMID: 31496620 DOI: 10.3748/wjg.v25.i31.4405]

32 **Nitta T**, Mitsuhashi T, Hatanaka Y, Hirano S, Matsuno Y. Pancreatic ductal adenocarcinomas with multiple large cystic structures: a clinicopathologic and immunohistochemical study of seven cases. *Pancreatology* 2013; **13**: 401-408 [PMID: 23890139 DOI: 10.1016/j.pan.2013.05.004]

33 **Bagci P**, Andea AA, Basturk O, Jang KT, Erbarut I, Adsay V. Large duct type invasive adenocarcinoma of the pancreas with microcystic and papillary patterns: a potential microscopic mimic of non-invasive ductal neoplasia. *Mod Pathol* 2012; **25**: 439-448 [PMID: 22056954 DOI: 10.1038/modpathol.2011.181]

34 **Kelly PJ**, Shinagare S, Sainani N, Hong X, Ferrone C, Yilmaz O, Fernández-del Castillo C, Lauwers GY, Deshpande V. Cystic papillary pattern in pancreatic ductal adenocarcinoma: a heretofore undescribed morphologic pattern that mimics intraductal papillary mucinous carcinoma. *Am J Surg Pathol* 2012; **36**: 696-701 [PMID: 22367300 DOI: 10.1097/PAS.0b013e318249ce1c]

35 **Kosmahl M**, Pauser U, Anlauf M, Klöppel G. Pancreatic ductal adenocarcinomas with cystic features: neither rare nor uniform. *Mod Pathol* 2005; **18**: 1157-1164 [PMID: 15920540 DOI: 10.1038/modpathol.3800446]

36 **Adsay V**, Logani S, Sarkar F, Crissman J, Vaitkevicius V. Foamy gland pattern of pancreatic ductal adenocarcinoma: a deceptively benign-appearing variant. *Am J Surg Pathol* 2000; **24**: 493-504 [PMID: 10757396 DOI: 10.1097/00000478-200004000-00003]

37 **Greenlee RT,** Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. *CA Cancer J Clin* 2000; **50:** 7-33 [PMID: 10735013 DOI: 10.3322/canjclin.50.1.7]

38 **Youn SY**, Rha SE, Jung ES, Lee IS. Pancreas ductal adenocarcinoma with cystic features on cross-sectional imaging: radiologic-pathologic correlation. *Diagn Interv Radiol* 2018; **24**: 5-11 [PMID: 29317372 DOI: 10.5152/dir.2018.17250]

39 **Kovač JD,** Janković A, Mašulović D. The “bunch of grapes” pattern of branch-duct IPMN. *Abdom Radiol (NY)* 2019; **45:** 249-250 [PMID: 31605187 DOI: 10.1007/s00261-019-02266-y]

40 **Chakravarthy S**, Chakravarty R, Sarkar N, Chitrotpala R. Radiological diagnosis of rare pancreatic serous cystadenoma. *J Family Med Prim Care* 2019; **8**: 2744-2746 [PMID: 31548970 DOI: 10.4103/jfmpc.jfmpc\_454\_19]

41 **Tanaka M**, Fernández-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, Kimura W, Levy P, Pitman MB, Schmidt CM, Shimizu M, Wolfgang CL, Yamaguchi K, Yamao K; International Association of Pancreatology. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. *Pancreatology* 2012; **12**: 183-197 [PMID: 22687371 DOI: 10.1016/j.pan.2012.04.004]

42 **Ånonsen K**, Sahakyan MA, Kleive D, Waage A, Verbeke C, Hauge T, Buanes T, Edwin B, Labori KJ. Trends in management and outcome of cystic pancreatic lesions - analysis of 322 cases undergoing surgical resection. *Scand J Gastroenterol* 2019; **54**: 1051-1057 [PMID: 31322457 DOI: 10.1080/00365521.2019.1642379]

43 **Yamao K**, Yanagisawa A, Takahashi K, Kimura W, Doi R, Fukushima N, Ohike N, Shimizu M, Hatori T, Nobukawa B, Hifumi M, Kobayashi Y, Tobita K, Tanno S, Sugiyama M, Miyasaka Y, Nakagohri T, Yamaguchi T, Hanada K, Abe H, Tada M, Fujita N, Tanaka M. Clinicopathological features and prognosis of mucinous cystic neoplasm with ovarian-type stroma: a multi-institutional study of the Japan pancreas society. *Pancreas* 2011; **40**: 67-71 [PMID: 20924309 DOI: 10.1097/MPA.0b013e3181f749d3]

44 **Rana SS**, Bhasin DK, Sharma R, Gupta R. Factors determining recurrence of fluid collections following migration of intended long term transmural stents in patients with walled off pancreatic necrosis and disconnected pancreatic duct syndrome. *Endosc Ultrasound* 2015; **4**: 208-212 [PMID: 26374578 DOI: 10.4103/2303-9027.162999]

45 **Cohen-Scali F**, Vilgrain V, Brancatelli G, Hammel P, Vullierme MP, Sauvanet A, Menu Y. Discrimination of unilocular macrocystic serous cystadenoma from pancreatic pseudocyst and mucinous cystadenoma with CT: initial observations. *Radiology* 2003; **228**: 727-733 [PMID: 12954892 DOI: 10.1148/radiol.2283020973]

46 **Kim YS**, Cho JH. Rare nonneoplastic cysts of pancreas. *Clin Endosc* 2015; **48**: 31-38 [PMID: 25674524 DOI: 10.5946/ce.2015.48.1.31]

47 **Assifi MM**, Nguyen PD, Agrawal N, Dedania N, Kennedy EP, Sauter PK, Prestipino A, Winter JM, Yeo CJ, Lavu H. Non-neoplastic epithelial cysts of the pancreas: a rare, benign entity. *J Gastrointest Surg* 2014; **18**: 523-531 [PMID: 24449000 DOI: 10.1007/s11605-014-2459-7]

48 **Young MR**, Wagner PD, Ghosh S, Rinaudo JA, Baker SG, Zaret KS, Goggins M, Srivastava S. Validation of Biomarkers for Early Detection of Pancreatic Cancer: Summary of The Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection Workshop. *Pancreas* 2018; **47**: 135-141 [PMID: 29346214 DOI: 10.1097/MPA.0000000000000973]

49 **Yoon SE**, Byun JH, Kim KA, Kim HJ, Lee SS, Jang SJ, Jang YJ, Lee MG. Pancreatic ductal adenocarcinoma with intratumoral cystic lesions on MRI: correlation with histopathological findings. *Br J Radiol* 2010; **83**: 318-326 [PMID: 19620175 DOI: 10.1259/bjr/69770140]

50 **Salvia R**, Crippa S, Partelli S, Armatura G, Malleo G, Paini M, Pea A, Bassi C. Differences between main-duct and branch-duct intraductal papillary mucinous neoplasms of the pancreas. *World J Gastrointest Surg* 2010; **2**: 342-346 [PMID: 21160841 DOI: 10.4240/wjgs.v2.i10.342]

51 **Laurent L,** Vullierme MP, Rebours V, Maire F, Hentic O, Francoz C, Durand F, Ruszniewski P, Levy P. Estimation of the prevalence of intraductal papillary mucinous neoplasm of the pancreas in the French population through patients waiting for liver transplantation. *United European Gastroenterol J* 2017; **5:** 499-503 [PMID: 28588880 DOI: 10.1177/2050640616664842]

52 **Wang Y**, Miller FH, Chen ZE, Merrick L, Mortele KJ, Hoff FL, Hammond NA, Yaghmai V, Nikolaidis P. Diffusion-weighted MR imaging of solid and cystic lesions of the pancreas. *Radiographics* 2011; **31**: E47-E64 [PMID: 21721197 DOI: 10.1148/rg.313105174]

53 **Morelli L**, Guadagni S, Borrelli V, Pisano R, Di Franco G, Palmeri M, Furbetta N, Gambaccini D, Marchi S, Boraschi P, Bastiani L, Campatelli A, Mosca F, Di Candio G. Role of abdominal ultrasound for the surveillance follow-up of pancreatic cystic neoplasms: a cost-effective safe alternative to the routine use of magnetic resonance imaging. *World J Gastroenterol* 2019; **25**: 2217-2228 [PMID: 31143072 DOI: 10.3748/wjg.v25.i18.2217]

54 **Kitano M**, Yoshida T, Itonaga M, Tamura T, Hatamaru K, Yamashita Y. Impact of endoscopic ultrasonography on diagnosis of pancreatic cancer. *J Gastroenterol* 2019; **54**: 19-32 [PMID: 30406288 DOI: 10.1007/s00535-018-1519-2]

55 **Kadiyala V**, Lee LS. Endosonography in the diagnosis and management of pancreatic cysts. *World J Gastrointest Endosc* 2015; **7**: 213-223 [PMID: 25789091 DOI: 10.4253/wjge.v7.i3.213]

56 **Will U**, Reichel A, Fueldner F, Meyer F. Endoscopic ultrasonography-guided drainage for patients with symptomatic obstruction and enlargement of the pancreatic duct. *World J Gastroenterol* 2015; **21**: 13140-13151 [PMID: 26674313 DOI: 10.3748/wjg.v21.i46.13140]

57 **Tsujino T**, Chang KJ. Cyst-Within-Cyst Found on EUS-Guided Cystoscopy of a Pancreatic Mucinous Cystic Neoplasia. *Am J Gastroenterol* 2016; **111**: 1089 [PMID: 27481409 DOI: 10.1038/ajg.2016.149]

58 **Sbeit W**, Kadah A, Farraj M, Shiller M. Pancreatic Cyst Mucin Ball Aspiration as a Diagnostic Maneuver. *Isr Med Assoc J* 2018; **20**: 394 [PMID: 29911766]

59 **Tanaka M**, Fernández-Del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T, Salvia R, Shimizu Y, Tada M, Wolfgang CL. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. *Pancreatology* 2017; **17**: 738-753 [PMID: 28735806 DOI: 10.1016/j.pan.2017.07.007]

60 **Gao RY**, Wu BH, Shen XY, Peng TL, Li DF, Wei C, Yu ZC, Luo MH, Xiong F, Wang LS, Yao J. Overlooked risk for needle tract seeding following endoscopic ultrasound-guided minimally invasive tissue acquisition. *World J Gastroenterol* 2020; **26**: 6182-6194 [PMID: 33177792 DOI: 10.3748/wjg.v26.i40.6182]

61 **Singhi AD**, Chu LC, Tatsas AD, Shi C, Ellison TA, Fishman EK, Kawamoto S, Schulick RD, Wolfgang CL, Hruban RH, Edil BH. Cystic pancreatic neuroendocrine tumors: a clinicopathologic study. *Am J Surg Pathol* 2012; **36**: 1666-1673 [PMID: 23073325 DOI: 10.1097/PAS.0b013e31826a0048]

62 **Halfdanarson TR**, Rubin J, Farnell MB, Grant CS, Petersen GM. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. *Endocr Relat Cancer* 2008; **15**: 409-427 [PMID: 18508996 DOI: 10.1677/ERC-07-0221]

63 **Furukawa T**, Klöppel G, Volkan Adsay N, Albores-Saavedra J, Fukushima N, Horii A, Hruban RH, Kato Y, Klimstra DS, Longnecker DS, Lüttges J, Offerhaus GJ, Shimizu M, Sunamura M, Suriawinata A, Takaori K, Yonezawa S. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. *Virchows Arch* 2005; **447**: 794-799 [PMID: 16088402 DOI: 10.1007/s00428-005-0039-7]

64 **Furukawa T**, Hatori T, Fujita I, Yamamoto M, Kobayashi M, Ohike N, Morohoshi T, Egawa S, Unno M, Takao S, Osako M, Yonezawa S, Mino-Kenudson M, Lauwers GY, Yamaguchi H, Ban S, Shimizu M. Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. *Gut* 2011; **60**: 509-516 [PMID: 21193453 DOI: 10.1136/gut.2010.210567]

65 **Adsay NV**, Merati K, Nassar H, Shia J, Sarkar F, Pierson CR, Cheng JD, Visscher DW, Hruban RH, Klimstra DS. Pathogenesis of colloid (pure mucinous) carcinoma of exocrine organs: Coupling of gel-forming mucin (MUC2) production with altered cell polarity and abnormal cell-stroma interaction may be the key factor in the morphogenesis and indolent behavior of colloid carcinoma in the breast and pancreas. *Am J Surg Pathol* 2003; **27**: 571-578 [PMID: 12717243 DOI: 10.1097/00000478-200305000-00002]

66 **Adsay NV**, Pierson C, Sarkar F, Abrams J, Weaver D, Conlon KC, Brennan MF, Klimstra DS. Colloid (mucinous noncystic) carcinoma of the pancreas. *Am J Surg Pathol* 2001; **25**: 26-42 [PMID: 11145249 DOI: 10.1097/00000478-200101000-00003]

67 **Rana SS**, Sharma V, Sharma R, Gupta R, Bhasin DK. Endoscopic ultrasound guided transmural drainage of walled off pancreatic necrosis using a "step - up" approach: A single centre experience. *Pancreatology* 2017; **17**: 203-208 [PMID: 28202234 DOI: 10.1016/j.pan.2017.02.007]

68 **Lau SK**, Weiss LM, Chu PG. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. *Am J Clin Pathol* 2004; **122**: 61-69 [PMID: 15272531 DOI: 10.1309/9R66-73QE-C06D-86Y4]

69 **Haeberle L**, Esposito I. Pathology of pancreatic cancer. *Transl Gastroenterol Hepatol* 2019; **4**: 50 [PMID: 31304427 DOI: 10.21037/tgh.2019.06.02]

70 **Morris JP 4th**, Cano DA, Sekine S, Wang SC, Hebrok M. Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. *J Clin Invest* 2010; **120**: 508-520 [PMID: 20071774 DOI: 10.1172/JCI40045]

71 **Kopp JL**, von Figura G, Mayes E, Liu FF, Dubois CL, Morris JP 4th, Pan FC, Akiyama H, Wright CV, Jensen K, Hebrok M, Sander M. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. *Cancer Cell* 2012; **22**: 737-750 [PMID: 23201164 DOI: 10.1016/j.ccr.2012.10.025]

72 **Kanda M**, Matthaei H, Wu J, Hong SM, Yu J, Borges M, Hruban RH, Maitra A, Kinzler K, Vogelstein B, Goggins M. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. *Gastroenterology* 2012; **142**: 730-733.e9 [PMID: 22226782 DOI: 10.1053/j.gastro.2011.12.042]

73 **Kuboki Y**, Shimizu K, Hatori T, Yamamoto M, Shibata N, Shiratori K, Furukawa T. Molecular biomarkers for progression of intraductal papillary mucinous neoplasm of the pancreas. *Pancreas* 2015; **44**: 227-235 [PMID: 25423558 DOI: 10.1097/MPA.0000000000000253]

74 **Tsuda M**, Fukuda A, Roy N, Hiramatsu Y, Leonhardt L, Kakiuchi N, Hoyer K, Ogawa S, Goto N, Ikuta K, Kimura Y, Matsumoto Y, Takada Y, Yoshioka T, Maruno T, Yamaga Y, Kim GE, Akiyama H, Ogawa S, Wright CV, Saur D, Takaori K, Uemoto S, Hebrok M, Chiba T, Seno H. The BRG1/SOX9 axis is critical for acinar cell-derived pancreatic tumorigenesis. *J Clin Invest* 2018; **128**: 3475-3489 [PMID: 30010625 DOI: 10.1172/JCI94287]

75 **Redston MS**, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, Kern SE. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. *Cancer Res* 1994; **54**: 3025-3033 [PMID: 8187092]

76 **Furukawa T**, Fujisaki R, Yoshida Y, Kanai N, Sunamura M, Abe T, Takeda K, Matsuno S, Horii A. Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. *Mod Pathol* 2005; **18**: 1034-1042 [PMID: 15832194 DOI: 10.1038/modpathol.3800383]

77 **Walerych D**, Lisek K, Sommaggio R, Piazza S, Ciani Y, Dalla E, Rajkowska K, Gaweda-Walerych K, Ingallina E, Tonelli C, Morelli MJ, Amato A, Eterno V, Zambelli A, Rosato A, Amati B, Wiśniewski JR, Del Sal G. Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. *Nat Cell Biol* 2016; **18**: 897-909 [PMID: 27347849 DOI: 10.1038/ncb3380]

78 **Escobar-Hoyos LF**, Penson A, Kannan R, Cho H, Pan CH, Singh RK, Apken LH, Hobbs GA, Luo R, Lecomte N, Babu S, Pan FC, Alonso-Curbelo D, Morris JP 4th, Askan G, Grbovic-Huezo O, Ogrodowski P, Bermeo J, Saglimbeni J, Cruz CD, Ho YJ, Lawrence SA, Melchor JP, Goda GA, Bai K, Pastore A, Hogg SJ, Raghavan S, Bailey P, Chang DK, Biankin A, Shroyer KR, Wolpin BM, Aguirre AJ, Ventura A, Taylor B, Der CJ, Dominguez D, Kümmel D, Oeckinghaus A, Lowe SW, Bradley RK, Abdel-Wahab O, Leach SD. Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. *Cancer Cell* 2020; **38**: 198-211.e8 [PMID: 32559497 DOI: 10.1016/j.ccell.2020.05.010]

79 **Bardeesy N**, Cheng KH, Berger JH, Chu GC, Pahler J, Olson P, Hezel AF, Horner J, Lauwers GY, Hanahan D, DePinho RA. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. *Genes Dev* 2006; **20**: 3130-3146 [PMID: 17114584 DOI: 10.1101/gad.1478706]

80 **Wu J**, Matthaei H, Maitra A, Dal Molin M, Wood LD, Eshleman JR, Goggins M, Canto MI, Schulick RD, Edil BH, Wolfgang CL, Klein AP, Diaz LA Jr, Allen PJ, Schmidt CM, Kinzler KW, Papadopoulos N, Hruban RH, Vogelstein B. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. *Sci Transl Med* 2011; **3**: 92ra66 [PMID: 21775669 DOI: 10.1126/scitranslmed.3002543]

81 **Furukawa T**, Kuboki Y, Tanji E, Yoshida S, Hatori T, Yamamoto M, Shibata N, Shimizu K, Kamatani N, Shiratori K. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. *Sci Rep* 2011; **1**: 161 [PMID: 22355676 DOI: 10.1038/srep00161]

82 **Patra KC**, Kato Y, Mizukami Y, Widholz S, Boukhali M, Revenco I, Grossman EA, Ji F, Sadreyev RI, Liss AS, Screaton RA, Sakamoto K, Ryan DP, Mino-Kenudson M, Castillo CF, Nomura DK, Haas W, Bardeesy N. Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. *Nat Cell Biol* 2018; **20**: 811-822 [PMID: 29941929 DOI: 10.1038/s41556-018-0122-3]

83 **Amato E**, Molin MD, Mafficini A, Yu J, Malleo G, Rusev B, Fassan M, Antonello D, Sadakari Y, Castelli P, Zamboni G, Maitra A, Salvia R, Hruban RH, Bassi C, Capelli P, Lawlor RT, Goggins M, Scarpa A. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. *J Pathol* 2014; **233**: 217-227 [PMID: 24604757 DOI: 10.1002/path.4344]

84 **Lee JH**, Kim Y, Choi JW, Kim YS. KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis. *Springerplus* 2016; **5**: 1172 [PMID: 27512631 DOI: 10.1186/s40064-016-2847-4]

85 **Wu J**, Jiao Y, Dal Molin M, Maitra A, de Wilde RF, Wood LD, Eshleman JR, Goggins MG, Wolfgang CL, Canto MI, Schulick RD, Edil BH, Choti MA, Adsay V, Klimstra DS, Offerhaus GJ, Klein AP, Kopelovich L, Carter H, Karchin R, Allen PJ, Schmidt CM, Naito Y, Diaz LA Jr, Kinzler KW, Papadopoulos N, Hruban RH, Vogelstein B. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. *Proc Natl Acad Sci U S A* 2011; **108**: 21188-21193 [PMID: 22158988 DOI: 10.1073/pnas.1118046108]

86 **Scarpa A**, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, Lawlor RT, Johns AL, Miller DK, Mafficini A, Rusev B, Scardoni M, Antonello D, Barbi S, Sikora KO, Cingarlini S, Vicentini C, McKay S, Quinn MCJ, Bruxner TJC, Christ AN, Harliwong I, Idrisoglu S, McLean S, Nourse C, Nourbakhsh E, Wilson PJ, Anderson MJ, Fink JL, Newell F, Waddell N, Holmes O, Kazakoff SH, Leonard C, Wood S, Xu Q, Hiriyur Nagaraj S, Amato E, Dalai I, Bersani S, Cataldo I, Dei Tos AP, Capelli P, Vittoria Davì M, Landoni L, Malpaga A, Miotto M, Whitehall VLJ, Leggett BA, Harris JL, Harris J, Jones MD, Humphris J, Chantrill LA, Chin V, Nagrial AM, Pajic M, Scarlett CJ, Pinho A, Rooman I, Toon C, Wu J, Pinese M, Cowley M, Barbour A, Mawson A, Humphrey ES, Colvin EK, Chou A, Lovell JA, Jamieson NB, Duthie F, Gingras MC, Fisher WE, Dagg RA, Lau LMS, Lee M, Pickett HA, Reddel RR, Samra JS, Kench JG, Merrett ND, Epari K, Nguyen NQ, Zeps N, Falconi M, Simbolo M, Butturini G, Van Buren G, Partelli S, Fassan M; Australian Pancreatic Cancer Genome Initiative, Khanna KK, Gill AJ, Wheeler DA, Gibbs RA, Musgrove EA, Bassi C, Tortora G, Pederzoli P, Pearson JV, Waddell N, Biankin AV, Grimmond SM. Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours. *Nature* 2017; **550**: 548 [PMID: 28953865 DOI: 10.1038/nature24026]

87 **Pelosi E**, Castelli G, Testa U. Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. *Biomedicines* 2017; **5** [PMID: 29156578 DOI: 10.3390/biomedicines5040065]

88 **Lytle NK**, Ferguson LP, Rajbhandari N, Gilroy K, Fox RG, Deshpande A, Schürch CM, Hamilton M, Robertson N, Lin W, Noel P, Wartenberg M, Zlobec I, Eichmann M, Galván JA, Karamitopoulou E, Gilderman T, Esparza LA, Shima Y, Spahn P, French R, Lewis NE, Fisch KM, Sasik R, Rosenthal SB, Kritzik M, Von Hoff D, Han H, Ideker T, Deshpande AJ, Lowy AM, Adams PD, Reya T. A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma. *Cell* 2019; **177**: 572-586.e22 [PMID: 30955884 DOI: 10.1016/j.cell.2019.03.010]

89 **Jones S**, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science* 2008; **321**: 1801-1806 [PMID: 18772397 DOI: 10.1126/science.1164368]

90 **Okabayashi T**, Shima Y, Kosaki T, Sumiyoshi T, Kozuki A, Iiyama T, Takezaki Y, Kobayashi M, Nishimori I, Ogawa Y, Hanazaki K. Invasive carcinoma derived from branch duct-type IPMN may be a more aggressive neoplasm than that derived from main duct-type IPMN. *Oncol Lett* 2013; **5**: 1819-1825 [PMID: 23833648 DOI: 10.3892/ol.2013.1268]

91 **Oettle H**, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning MB, Sinn M, Hinke A, Riess H. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. *JAMA* 2013; **310**: 1473-1481 [PMID: 24104372 DOI: 10.1001/jama.2013.279201]

92 **Uesaka K**, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y; JASPAC 01 Study Group. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). *Lancet* 2016; **388**: 248-257 [PMID: 27265347 DOI: 10.1016/S0140-6736(16)30583-9]

93 **Eguchi H**, Takeda Y, Takahashi H, Nakahira S, Kashiwazaki M, Shimizu J, Sakai D, Isohashi F, Nagano H, Mori M, Doki Y. A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma. *Ann Surg Oncol* 2019; **26**: 4498-4505 [PMID: 31440928 DOI: 10.1245/s10434-019-07735-8]

**Footnotes**

**Conflict-of-interest statement:** There is no conflict of interest associated with any of the authors who contributed their efforts in this manuscript.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding Author's Membership in Professional Societies:** Japanese Society of Internal Medicine, No. 99021; Japanese Association for Medical Artificial Intelligence, No. 388; Japanese Board of Cancer Therapy, No. 1810053; Japan Gastroenterological Endoscopy Society, No. 20190318; The Japanese Society of Gastroenterology, No. 39625; and American Gastroenterological Association, No. 1156949.

**Peer-review started:** January 28, 2021

**First decision:** February 24, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Japan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A, A

Grade B (Very good): B, B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Ker CG, Neri V, Thosani N, Wang XB **S-Editor:** Fan JR **L-Editor: P-Editor:**

**Figure Legends**



**Figure 1 Typical computed tomography imaging of large-duct pancreatic ductal adenocarcinoma.** The yellow arrowheads show the cystic lesion in large-duct pancreatic ductal adenocarcinoma. A: Plain computed tomography indicates low attenuation area in the pancreas; B: Arterial phase reveals multiple cystic lesions in the pancreatic head without enhancement; C: Portal phase shows multiple cystic lesions in the pancreatic head with parenchymal enhancement; D: Equilibrium phase shows slight ring enhancement of the lesion.



**Figure 2 Typical magnetic resonance imaging of large-duct pancreatic ductal adenocarcinoma.** The yellow arrowheads show the cystic lesion in large-duct pancreatic ductal adenocarcinoma (PDA). A: T2-weighted imaging reveals high intensity in the large-duct PDA lesion; B: Diffusion-weighted imaging shows no significant signal increase/decrease in the lesion; C: Magnetic resonance cholangiopancreatography (coronal view) reveals multiple cystic lesions in the pancreatic head and compressed bile duct.



**Figure 3 Endoscopic ultrasonography findings of large-duct pancreatic ductal adenocarcinoma.** The yellow arrowhead shows the cystic lesion in large-duct pancreatic ductal adenocarcinoma (PDA). A: Endoscopic ultrasonography (EUS) reveals multiple echoic lesions in the pancreatic head; B: EUS-fine-needle aspiration was performed in the parenchyma of the cystic lesion in large-duct PDA. The EUS model used was GF-UE260-AL5 (Olympus, Tokyo, Japan). The ultrasonic diagnostic equipment used was EU-ME2 (Olympus, Tokyo, Japan). CBD: Common bile duct; MPD: Main pancreatic duct.

 



**Figure 4 Pathological findings of large-duct pancreatic ductal adenocarcinoma.** A: Hematoxylin–eosin (HE) staining of the lesion (× 4); B: HE staining of the lesion (× 200) shows a dilatated glandular carcinoma > 0.5 mm in diameter (black arrowhead); C: Elastica–Masson immunohistochemistry (× 200) reveals that the dilatated glands lack elastic fibers (black arrowhead); D: HE staining of the carcinoma invading the myelin sheath (× 200; black arrowhead); E: Elastica–Masson immunohistochemistry (× 200) reveals that the dilatated glands invading the myelin sheath lack elastic fibers (black arrowheads show the myelin fiber).

**Table 1 Patient characteristics of large-duct pancreatic ductal adenocarcinoma**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Number of cases** | **Median age** | **Sex** | **Tumor location** |
| **Female** | **Male** | **Head** | **Body or tail** |
| Kelly *et al*[34], 2012 | 10 | 67 | 6 | 4 | 9 | 1 |
| Bagci *et al*[33], 2012 | 28 | 67 | 191 | 81 | 16 | 11 |
| Kosmahl *et al*[35], 2005 | 24 | 58 | 15 | 9 | 122 | 92 |
| Total | 63 | 63.0 | 40 | 23 | 37 | 21 |

1One case with missing information on sex; 2Three cases with missing information on tumor location.

**Table 2 Clinical and morphological characteristics of pancreatic diseases**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Diseases** | **Median age** | **Sex (%, females)** | **Tumor location (%, pancreatic head)** | **Multifocality** | **Gross appearance** | **Cyst diameter** | **Main pancreatic duct communication** | **Internal structure** | **Other features** | **Key genetic alterations** |
| Bagci *et al*[33], 2012  | Large-duct PDA | 63 | 68.3 | 56.2 | No | Multiple small cysts | 0.5–0.7 cm in each cyst | No | Dilatated glandular cyst (duct) | Dilatated glandular cyst (duct) is > 0.5 mm in diameter. Easily invades to the perineural plexus and shows desmoplastic reaction | *KRAS* (codon 12) |
| Kelly *et al*[34], 2012 |
| Kosmahl *et al*[35]*,* 2005 |
| Youn *et al*[38], 2018  |
| Seidel *et al*[18], 2002  | Colloid carcinoma | 61 | 52.9 | 66.7 | Infrequent | Single or multiple cysts, well demarcated | 1.2–16 cm | No | Well-defined pools of mucin, contained scanty malignant epithelial cells | Associated with intestinal-type IPMN | *KRAS, BRAF, PIK3CA*; MSIs are more frequently observed than non-colloid cancer PDA  |
| Adsay *et al*[24], 2016  |
| Tanaka *et al*[41], 2012  | Branched duct-type IPMN | 65–70 | 55.2 | 62.3 | Yes | Bunch of grapes | Up to 30 mm for non-invasive IPMN; 30 mm or greater for IPMN with worrisome features | Yes | Cyst by cyst | Main pancreatic duct; normal or dilatated to > 5 mm, suggesting combined type with main duct IPMN | *KRAS* (codon 12), *GNAS*, *RNF43* |
| Kim andCho[46], 2015  |
| Laurent *et al*[51], 2016  |
| Hecht *et al*[19], 2021  | Main duct-type IPMN | 60 s | 41.3 | 59.6 | Yes | Bunch of grapes | Up to 30 mm for non-invasive IPMN; 30 mm or greater for IPMN with worrisome features | Yes | Cyst by cyst | Main pancreatic duct; partial or diffuse dilatation > 5 mm | *KRAS* (codon 12), *GNAS*, *RNF43, TP53* |
| Tanaka *et al*[41], 2012 |
| Salvia *et al*[50], 2010  |
| Ånonsen *et al*[42], 2019  | SCN | 60–70 | 70 | 50 | No | Spongy or honeycomb-like | 3.7–5.1 cm | No | Microcystic or macrocystic |  | *VHL* |
| Wu *et al*[80], 2011  |
| Ånonsen *et al*[42], 2019  | MCN | 40–50 | 95 | 5 | Infrequent | Orange-like | 1.0–26.4 cm | No | Cyst by cyst | Ovarian-like stroma | *KRAS, RNF43* |
| Yamao *et al*[43], 2011 |
| Wu *et al*[80], 2011 |
| Kim andCho[46], 2015 | Retention cyst | 60 s | ? | ? | No | Unilocular | 2.8–12 cm | Yes | No cellular dysplasia | Main pancreatic obstruction in should be observed downstream | ? |
| Assifi *et al*[47], 2014  |
| Singhi *et al*[61], 2012  | Pancreatic neuroendocrine neoplasms with cystic changes | 50 s | 42 | 24 | Infrequent, except MEN1-related neuroendocrine neoplasms | Pinkish-tan to yellowish in color, well demarcated | 0.8–18.0 cm | No | Well circumscribed and surrounded by a thin-to-thick fibrous capsule | Larger cysts tend to show hemorrhage | *MEN1, PTEN, DAXX, ATRX, MUTYH, CHEK2* |
| Halfdanarson *et al*[62], 2008  |
| Scarpa *et al*[86], 2017  |
| Tanaka *et al*[41], 2012 | Walled-off necrosis | 40–50 | 25 | 45 | Rare | Variable | Variable | Yes | Unilocular | Main pancreatic duct; normal or irregularly dilatated. Observed no later than 6 wk after the occurrence of acute pancreatitis |  |
| Cohen *et al*[45], 2003  |

PDA: Pancreatic ductal adenocarcinoma; IPMN: Intraductal papillary mucinous neoplasms; MCN: Mucinous cystic neoplasm; SCN: Solid cystic neoplasm.

**Table 3 Mucin staining profiles of large-duct pancreatic ductal adenocarcinoma**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **MUC1** | **MUC2** | **MUC5AC** | **MUC6** |
| Kelly *et al*[34], 2012 | 10/10 (100.0%) | 1/10 (90.0%) | 9/10 (90.0%) | 8/10 (80.0%) |
| Kosmahl *et al*[35], 2005 | 17/24 (70.8%) | 2/24 (8.3%) | 17/23 (73.1%) | 12/23 (52.2%) |
| Total | 27/37 (73.0%) | 3/37 (8.1%) | 26/36 (72.2%) | 20/36 (55.6%) |

No. of staining-positive cases/available cases. MUC: Mucin.